Biotechnology
Technology
Health

Kadmon

$2.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.13 (-4.98%) Today
$0.00 (0.00%) As of 4:02 PM EDT after-hours

Why Robinhood?

You can buy or sell Kadmon and other stocks, options, ETFs, and crypto commission-free!

About KDMN

Kadmon Holdings, Inc., also called Kadmon, is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. It focuses on the treatment of autoimmune, inflammatory, and fibrotic diseases. Read More Its products include Ribasphere, RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine. The company was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.

Employees
116
Headquarters
New York, New York
Founded
2010
Market Cap
314.74M
Price-Earnings Ratio
Dividend Yield
Average Volume
947.03K
High Today
$2.69
Low Today
$2.46
Open Price
$2.62
Volume
587.56K
52 Week High
$4.39
52 Week Low
$1.63

Collections

Biotechnology
Technology
Health
2016 IPO
US
North America

KDMN News

Yahoo FinanceJun 23

Hedge Funds Have Never Been This Bullish On Kadmon Holdings, Inc.

164

KDMN Earnings

-$0.37
-$0.24
-$0.11
$0.02
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours

More KDMN News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.